PPGN — PolyPeptide AG Cashflow Statement
0.000.00%
Last trade - 00:00- CH₣821.86m
- CH₣882.73m
- €391.95m
Annual cashflow statement for PolyPeptide AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 47.3 | 7.77 | -51.4 | -19.6 | -21.2 |
| Depreciation | |||||
| Non-Cash Items | 22.7 | 6.83 | 16.7 | 13.7 | 32.8 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -33.3 | -35.2 | 40.7 | 62.5 | 27.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 57.4 | 5.46 | 36.5 | 89.4 | 77.5 |
| Capital Expenditures | -77.7 | -78.8 | -56.7 | -87 | -109 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -3.14 | 0.329 | -2.78 | -4.05 | -2.81 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -80.8 | -78.4 | -59.5 | -91 | -112 |
| Financing Cash Flow Items | -4.38 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 131 | -26.9 | 84.5 | -25.3 | 33.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 119 | -98.8 | 58.2 | -27.4 | 6.31 |